Testing asciminib with trastuzumab for HER2+ breast cancer that has spread to the brain
Official title: Asciminib in HER2+ Breast Cancer Brain Metastases
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether two drugs given together can help brain tumors that came from HER2+ breast cancer.
Read our full plain-language summary
What the trial team says
The purpose of this study is to evaluate the intracranial response rate of a combination of asciminib/trastuzumab for the treatment of patients with metastatic HER2+ breast cancer with brain metastases.
Key facts
- Registry number
- NCT07136428
- Stage of testing
- Phase 1/Phase 2
- Conditions studied
- HER2+ Metastatic Breast Cancer
Where it is running
This trial lists 1 site.
-
North Carolina
- Duke University (Durham)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.